Paclitaxel

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Retrieved on: 
화요일, 4월 9, 2024
BID, Patient, Fluorouracil, 3D, MIA, Cancer, AACR, TGI, Pancreatic cancer, Paclitaxel, TGA, Annual general meeting, Medical imaging

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.

Key Points: 
  • “We are evaluating a broad range of combinations for a variety of cancer types in our humanized 3D tumor growth assays, together with animal models.
  • The data we are sharing today at AACR clearly demonstrates IMM-1-104’s potential in combination with chemotherapy for pancreatic cancer.
  • IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models.
  • IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.

Bio-Path Holdings Provides 2024 Clinical and Operational Update

Retrieved on: 
화요일, 4월 2, 2024
Toxicity, Obesity, Drug discovery, Chronic lymphocytic leukemia, Survival, CLL, AML, Fast track (FDA), Insulin, Patient, New York Medical College, Biomarker, Cancer, Leukemia, IND, University, Lymphoma, Pancreatic cancer, Clinical trial, Paclitaxel, Potential, Breast cancer, Safety, RNA interference, GRB2, Holding, Leptin, Probability, FDA, STAT3, Stage 4, Food, Pharmaceutical industry

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.

Key Points: 
  • HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.
  • Prexigebersen Phase 2 Clinical Trial – Bio-Path’s Phase 2 clinical trial is treating Acute Myeloid Leukemia (AML) patients.
  • Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML – A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing.
  • In January 2024, Bio-Path announced successful completion of the first dose cohort in the Phase 1 clinical trial.

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

Retrieved on: 
금요일, 3월 29, 2024
CPS, Patient, Lung cancer, IND, Infection, Cancer, Investment, Cisplatin, Paclitaxel, Melanoma, Marketing, RNA, New chemical entity, Gentlemen's agreement, NRDL, Food, Therapeutic Goods Administration, Biologics license application, Insurance, Research, Junshi, National Medical Products Administration, TGA, FDA, NMPA, Tablet, COVID-19, NPC, Spacecraft, DSM-IV codes, Dacarbazine, Axitinib, Total, Pharmaceutical industry

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.

Key Points: 
  • SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.
  • Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022.
  • Loss attributable to owners was RMB2,282 million in 2023, representing a decrease of RMB104 million compared to the previous year.
  • This application was later approved for marketing in December 2023, marking the first and only approved perioperative therapy for lung cancer domestically.

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
월요일, 4월 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
목요일, 3월 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 3월 21, 2024
Biopsy, NSCLC, Entrepreneurship, Carcinoma, DLL4, Patient, Neoplasm, PET, Merck, G&A, Doctor of Philosophy, MD, Insurance, IND, Mesothelioma, Research and development, CD137, Therapy, Paclitaxel, BTC, CRC, Melanoma, Stage 2, PD-L1, FDA, SCLC, PD-1, Pharmaceutical industry

Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.

Key Points: 
  • Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update.
  • The increase was primarily attributable to higher stock compensation expense of $1.0 million offset by lower insurance costs of $0.3 million.
  • During 2023, the Company decreased its cash position by $34.1 million, primarily from $40.6 million of net cash used in operating activities.

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Retrieved on: 
수요일, 3월 20, 2024
Cancer, Drug discovery, Patient, SAN, Inflammation, Poster, Biochemistry, Clinical trial, Therapy, Paclitaxel, Safety, ACS, American Chemical Society, Lymphoma, Pharmaceutical industry

SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA. This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.

Key Points: 
  • This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.
  • “Today’s presentation at the ACS meeting showcases Nurix’s innovative combination of structure-based-drug-design and industry-leading expertise in the biochemistry of E3 ligases,” noted Gwenn Hansen, Ph.D., Nurix’s chief scientific officer.
  • This mechanism of action is notable because CBL-B lacks a classic enzymatic active site binding pocket, preventing typical inhibitor design and thereby requiring a novel drug discovery approach.
  • A copy of the presentation is available on the Posters and Presentations section of the scientific resources page of Nurix’s website.

Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024

Retrieved on: 
월요일, 4월 1, 2024
Research, Medical Devices, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Lung cancer, Corporation, CRL, 3D, Doctor of Philosophy, Digital twin, IND, AACR, PDX, Paclitaxel, NCG, Poster, San Diego Convention Center, Corporate development, Medical imaging

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting .
  • Charles River will present technology-driven capabilities and highlight the latest advancements in immuno-oncology, in vitro assays, and more.
  • The meeting is taking place from April 5-10, 2024, at the San Diego Convention Center in San Diego, California.
  • To learn more about Charles River’s research tools and services portfolio, visit booth #1121 at the AACR Annual Meeting 2024.

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Retrieved on: 
수요일, 3월 20, 2024
Research, General Health, Pharmaceutical, Oncology, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Practice Management, Other Science, Health, Fulvestrant, Carcinoma, Progression-free survival, Patient, JAMA Oncology, Pharming, Biomarker, CDK, Letrozole, IND, Triple-negative breast cancer, Puma Biotechnology, Cancer, Paclitaxel, Breast cancer, Anastrozole, Tamoxifen, FDA, Food, Pharmaceutical industry

This trial will investigate alisertib in combination with endocrine treatment (consisting of either anastrozole, exemestane, letrozole, fulvestrant or tamoxifen) in chemotherapy-naïve patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer.

Key Points: 
  • This trial will investigate alisertib in combination with endocrine treatment (consisting of either anastrozole, exemestane, letrozole, fulvestrant or tamoxifen) in chemotherapy-naïve patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer.
  • Puma plans to initiate this trial in the second half of 2024.
  • Patients must not have been previously treated with the endocrine treatment that will be given in combination with alisertib in the trial.
  • We look forward to the initiation of the ALISCA-Breast1 trial in the second half of 2024.”
    Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, “We are excited to move forward with the development of alisertib in HER2-negative hormone receptor-positive metastatic breast cancer.

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Retrieved on: 
월요일, 3월 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, Catholic higher education, Congress, Survival, Partnership, Patient, Doxorubicin, Doctor of Philosophy, Overalls, PROC, Clinical trial, Paclitaxel, ESGO, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona.
  • Of the 558 total patients enrolled in the INNOVATE-3 clinical trial, 201 patients (36%) were PLD-naïve.
  • “We are extremely pleased to share these data with our colleagues at ESGO and humbled by the selection for a best oral presentation session,” said primary investigator Professor Ignace Vergote, MD, PhD, Professor at the Catholic University of Leuven, Belgium.
  • “I would like to thank our collaborators, ENGOT and The GOG Foundation, for their partnership designing and conducting the INNOVATE-3 trial.